Picture loading failed.

Anti-MET therapeutic antibody (Pre-made Telisotuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Telisotuzumab vedotin, also known as ABBV 399 (ABBV-399; ABT 399), is a novel, first-in-class, investigational antibody-drug conjugate being developed by AbbVie comprised of the anti-c-Met antibody, ABT-700, directed against the cell surface glycoprotein mesothelia, conjugated to monomethyl auristatin E (MMAE) for the treatment of patients with solid tumors.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-559-1mg 1mg Inquiry
GMP-Bios-ab-559-10mg 10mg Inquiry
GMP-Bios-ab-559-100mg 100mg Inquiry
GMP-Bios-ab-559-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-MET therapeutic antibody (Pre-made Telisotuzumab biosimilar,Whole mAb ADC)
INN Name Telisotuzumab
TargetMET
FormatWhole mAb ADC
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesPierre Fabre;AbbVie
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours
Development Techna